Cathie Wood, of ARK Genomic Revolution ETF(NYSE: ARKG) explains the multi-trillion dollar opportunity in the Genomics Revolution: CAR-T, CRISPR, and DNA Sequencing
The $TRILLION Opportunity in CRISPR & DNA Sequencing Technologies
Newsmakers
CytoDyn’s (OTC: CYDY) Lead Product Candidate Leronlimab (PRO 140) Inhibits Colon Carcinoma Metastases to Liver and Lung in Preclinical Studies
CytoDyn will file for expanded access IND for patients with pancreatic, prostate, lung, breast, liver and melanoma cancers VANCOUVER, Washington, Nov 19, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology […]
Investing Strategy
“Is Tesla the Next Enron?” Two Notable Short Sellers Discuss the Possibilities
Quoth The Raven Research (Christopher Irons) interviews Montana Skeptic, a well known Tesla skeptic and short seller who writes frequently on Seeking Alpha and has over 4,000 followers. He manages a $1B+ portfolio for a […]
Healthcare
CytoDyn (OTC: CYDY) Files Pivotal Trial Protocol for HIV Monotherapy with FDA
VANCOUVER, Washington, May 15, 2019 — After four years of monotherapy trials, data is now available to submit the long-anticipated pivotal trial for monotherapy to the FDA Trial will include 10 weeks of induction therapy […]